At the 2025 World Sleep Congress in Singapore, our investigators highlighted the powerful intersections of sleep, epilepsy, and circadian health.

Emmanuel During, MD, an associate professor of neurology at the Icahn School of Medicine at Mount Sinai, discussed the external validation of an actigraphy-based classifier for diagnosing iRBD and its implications for scalable neurodegenerative screening.

Dr. Lynn Marie Trotti has been named the new Director of the Emory Sleep Center, succeeding Dr. Nancy Collop, who retires after 15 years of transformative leadership.

We’re thrilled to share that Dr. Susan Criswell, Co-Leader of the NAPS Consortium’s Neuroimaging Core, has been named Chief Medical Officer for Clinical Research at Barrow Neurological Institute.

New research shows that REM sleep behavior disorder (RBD) takes a toll not only on people with Parkinson’s disease but also on their partners.

A recent study by NAPS Investigators Drs. Trotti and Bilwise from Emory University, following 323 adults over ~2.5 years, found that symptoms of idiopathic hypersomnia remain largely stable.

New research highlights the role of the gut in Parkinson’s disease subtypes.

Using metabolomics, scientists compared blood samples from Parkinson’s patients with and without REM sleep behavior disorder (RBD).

Emmanuel During, MD, an associate professor of neurology at the Icahn School of Medicine at Mount Sinai, discussed the external validation of an actigraphy-based classifier for diagnosing iRBD and its implications for scalable neurodegenerative screening.

Acting out in your sleep? New guidelines could help keep you safe.

A simple skin swab could detect Parkinson’s up to 7 years before symptoms appear.

A groundbreaking study published in JAMA Neurology, led by Dr. Lee Neilson, a NAPS investigator at Oregon Health Sciences University, explores the connection between hearing loss and Parkinson's disease (PD) risk in over 3 million US veterans.

In early June, the American Academy of Sleep Medicine hosted the 39th Annual Meeting of the Associated Professional Sleep Societies, LLC (APSS), a joint event between the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS).

For nearly 40 years, the SLEEP annual meeting has been the leading networking event for sleep professionals across the globe. This year, SLEEP 2025 took place in Seattle, Washington, drawing global experts in sleep medicine and research, with several NAPS investigators and support teams contributing to the event's discussions.

Dr. Tanis Ferman, a NAPS Clinical Core investigator, co-authored a study exploring how dementia with Lewy bodies (DLB) symptoms differ between men and women in the two years before diagnosis.

New research from France highlights a promising brain scan technique – neuromelanin-sensitive MRI – that measures dopamine in a key brain region affected by Parkinson’s disease (PD).

Explore the latest consensus on managing RBD, led by NAPS Investigator Dr. Aleksandar Videnovic and the International RBD study group.

NAPS Consortium members took center stage, presenting on key topics and leading discussions on neurophysiology, RBD ethics, longitudinal data, and patient risk communication, just to name a few.

New research is shedding light on a potential breakthrough for diagnosing Parkinson's disease (PD). A study using surface-based fluorescence intensity distribution analysis (sFIDA) found that α-synuclein aggregates, commonly associated with PD, can be detected in urine samples.

The FDA has approved the first blood test to assist in diagnosing Alzheimer's.